Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1B Study
ReutersJun 23, 2025 11:05 AM
June 23 (Reuters) - Arrivent Biopharma Inc AVBP.O:
ARRIVENT ANNOUNCES POSITIVE INTERIM FIRMONERTINIB MONOTHERAPY DATA FROM GLOBAL PHASE 1B STUDY IN EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER AND PLANS TO ADVANCE INTO A GLOBAL PIVOTAL STUDY
ARRIVENT BIOPHARMA- ENROLLMENT OF FIRST PATIENT IN A RANDOMIZED, GLOBAL PIVOTAL PHASE 3 STUDY IN FIRST-LINE PACC PATIENTS EXPECTED IN H2 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Netflix After the Warner Deal: What Investors Should Know
TradingKey - For quite some time now, Netflix (NFLX) has been regarded as the premier subscription-based streaming service in the world, with a well-established history of growth through creative use of pricing power, developing hit programming, and relying very little on outside sources for licensiTradingKey
11 hours ago
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
Mon, Feb 9
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
